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ABSTRACT 
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BACKGROUND AND AIMS: People with opioid use disorder (OUD) in prison face an acute risk of 
death after release. We estimated whether prison-based opioid substitution treatment (OST) 
reduces this risk. 
 
DESIGN: Prospective observational cohort study using prison healthcare, national community drug 
misuse treatment and deaths registers.  
 
SETTING: Recruitment at 39 adult prisons in England (32 male; 7 female) accounting for 95% of 
OST treatment in England during study planning. 
 
PARTICIPANTS: Adult prisoners diagnosed with OUD (recruited: September 2010 to August 
2013; first release: September 2010; last release: October 2014; follow-up to February 2016; 
n=15,141 in the risk set). 
 
INTERVENTION AND COMPARATOR: At release, participants were classified as OST exposed 
(n=8,645) or OST unexposed (n=6,496). The OST unexposed group did not receive OST, or had 
been withdrawn, or had a low dose.  
MEASUREMENTS: Primary outcome: all-cause mortality (ACM) in the first 4 weeks. Secondary 
outcomes: drug-related poisoning (DRP) deaths in the first 4 weeks; ACM and DRP mortality after 
4 weeks to 1 year; admission to community drug misuse treatment in the first 4 weeks. Unadjusted 
and adjusted cox regression models (covariates: sex, age, drug injecting, problem alcohol use, use 
of benzodiazepines, cocaine, prison transfer and admission to community treatment), tested 
difference in mortality rates and community treatment uptake.  
FINDINGS: In the first 4 weeks after prison release, there were 24 ACM deaths: 6 in the OST 
exposed group and 18 in the OST unexposed group (mortality rate 0.93 per 100 person years [PY] 
versus 3.67 per 100 PY; Hazard Ratio [HR] 0.25; 95% Confidence interval [CI] 0.10 to 0.64). There 
were 18 DRP deaths: OST exposed group mortality rate 0.47 per 100 PY versus 3.06 per 100 PY 
in the OST unexposed group (HR 0.15; 95% CI 0.04 to 0.53). There was no group difference in 
mortality risk after the first month. The OST exposed group was more likely to enter drug misuse 
treatment in the first month post-release (odds ratio 2.47, 95% CI 2.31 to 2.65). The OST mortality 
protective effect on ACM and DRP mortality risk was not attenuated by demographic, overdose 
risk factors, prison transfer or community treatment (fully adjusted HR 0.25; 95% CI 0.09 to 0.64 
and HR 0.15; 95% CI 0.04 to 0.52, respectively). 
CONCLUSIONS: In an English national study, prison-based opioid substitution treatment was 
associated with a 75% reduction in all-cause mortality and an 85% reduction in fatal drug-related 
poisoning in the first month after release.  
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INTRODUCTION 
Non-medical opioid use contributes significantly to the global burden of disease [1]. Illicit heroin is 
associated with a high risk of death (particularly among people who inject drugs [2]), and this 
increases with age and in men [3]. The leading cause of death in this population is accidental drug 
poisoning (overdose) associated with acute respiratory depression, hypoventilation and hypoxia 
[4]. Opioid overdose is a major public health problem in many countries. The United States (USA) 
saw a four-fold increase in opioid poisoning deaths between 1999 and 2009 [5]. In England and 
Wales, the highest ever mortality rate from drug poisonings was recorded in 2015: 43.8 cases per 
million population [6].  
There is a very high prevalence of substance misuse in the prison population (globally: 10 to 48% 
for men and 30 to 60% for women [7]). Of concern is that prisoners with OUD face an acute risk of 
death on their release to the community. This is particularly high during the first month [8,9] and 
there is evidence that an elevated risk is seen across the first year [10].  
There are likely to be several causes. The most likely physiological mechanism is that the 
reduction, or complete reversal, of opioid tolerance during incarceration means that ex-prisoners 
are acutely vulnerable to fatal overdose if a pre-incarceration dose is consumed at liberty. 
Research has identified behavioural factors that also contribute: injecting an opioid acutely 
increases drug bioavailability and respiratory effects, and concurrent alcohol and benzodiazepine 
use can exacerbate suppression of the respiratory drive [11,12]; although concurrent cocaine use 
(common among illicit heroin users in the UK, USA and several other countries) can briefly 
antagonise respiratory suppression, this stimulant can induce life-threatening cardiovascular 
arrhythmias. Taken together, fatal drug-related poisoning (DRP) in this population can have a 
relatively straightforward or a more complex cause [13].  
Oral methadone and buprenorphine are the first-line, opioid agonist therapies for opioid use 
disorder (OUD; DSM-5 [14]; or the conceptually identical ‘opioid dependence’ diagnosis in ICD-10 
[15]). These opioid substitution treatment (OST) medications are associated with cessation or 
lower drug use and injecting [16]; a lower risk of acquiring blood borne viral infections [17], and 
reduced mortality in the community setting [18,19]. Most national healthcare systems offer OST for 
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OUD. In the England, illicit heroin is the main drug used by the OUD population, and OST (with 
adjunctive psychosocial interventions) is accessible in all local treatment systems [20].  
Between 2006 and 2010, an Integrated Drug Treatment System (IDTS) was introduced to provide 
OST in English prisons and to guide referral of prisoners to community drug misuse treatment 
services after their release [21]. OST in the IDTS involves oral methadone or buprenorphine for 
maintenance and (as indicated) withdrawal. Treatment is offered on a voluntarily basis according 
to a clinical assessment and the patient’s preference. OST is provided as continued maintenance 
from the community (or another prison), or as a new episode beginning at entry, or during 
incarceration. Prisoners receive an initial clinical screening by a member of the healthcare team 
and OUD diagnosis is confirmed by a doctor. The patient is then inducted onto OST as indicated. 
With prison-based drug misuse treatment interventions intended to mirror and link to the provision 
of treatment in the community, case descriptive information on all treatment episodes is now 
captured by the English National Drug Treatment Monitoring System (NDTMS). NDTMS includes 
almost all publicly funded service providers and provides outcome and performance monitoring for 
each local treatment system [22].   
Does prison-based OST exposure reduce post-release mortality? In 2012, a systematic review of 6 
experimental and 15 observational studies concluded that there was limited evidence [23]. This 
was because studies either lacked a means of identifying prisoners with OUD and who had had 
OST, or were unable to record overdose risk factors and subsequent treatment to isolate a 
treatment effect. English prison healthcare records and the NDTMS capture all this information 
enabling a robust observational, cohort design with statistical control of confounders. An 
experimental design (i.e. patients assigned to OST maintenance or withdrawal before prison 
release) was rejected because medication is received voluntarily in the IDTS and we considered it 
unethical to enforce withdrawal. 
Accordingly, in this large-scale national study our aims were:  
(1)  to estimate whether prison-based OST exposure at release reduces post-release mortality;   
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(2)  to estimate and compare the likelihood of admission to community drug-misuse treatment by 
OST exposure; and 
(3)  to estimate whether a protective effect of prison-based OST at release is confounded by 
relevant covariates and admission to community treatment. 
METHODS 
Design, prison sample, target population and exposure 
This was an English national prospective observational cohort study of prison-based OST 
exposure, reported following the STROBE guideline [24].  
In 2009, routine OST prescribing data compiled by the National Treatment Agency for Substance 
Misuse was used to identify the population of prisons providing OST. 45 prisons provided OST in 
that year. However, 2 had very small caseloads (i.e. <4 new episodes of treatment initiated per 
quarter) so we decided to exclude these. 43 prisons were approached to take part in the study (35 
male prisons and 8 female prisons).  
The target population was adult prisoners (≥18 years) with a diagnosis of OUD recorded on an 
electronic database at the prison. Allocation of the patient to methadone or buprenorphine is 
guided by clinical assessment and patient preference in the IDTS. Patient preference is usually 
informed by personal experience or beliefs about these medications; clinical history of response 
and drug-drug interaction issues with other medication may also point to one medication over the 
other. 
During planning, we were aware that some patients were released from prison with a low-dose 
prescription for methadone or buprenorphine. Efficacy trials of OST have included participants 
receiving 20 to 120 mg/day (methadone) and 2 to 16 mg/day (buprenorphine) [25]. Accordingly, we 
set >20 mg for methadone and >2 mg for buprenorphine as the dose threshold for classifying OST 
exposure for all prisoners at release.  
Prisoners who met the threshold (i.e. their last dose administered on the morning of release was 
>20mg methadone or >2mg buprenorphine) were classified as OST exposed. Prisoners with OUD 
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who had not received OST in prison, or had completed a medication withdrawal regimen while in 
prison, or had been prescribed less than the dose threshold on the day of release were classified 
as OST unexposed.  
Given the fluctuating nature of the English prison population – with people entering, some 
transferred to another prison, leaving, and some re-incarcerated – we expected a proportion of the 
study cohort to enter the risk set more than once during recruitment (see statistical analysis).  
Outcome measures 
We selected all-cause mortality (ACM) in the first 4 weeks following release (i.e. day 1 to 28), 
expressed as risk per 100 person years (PY), as the appropriate primary outcome measure. The 
null hypothesis was that there would be no difference in the ACM risk between the OST exposed 
and OST unexposed groups.  
Secondary outcome measures (also tested as null hypotheses) were as follows: 
(1) DRP mortality in the first 4 weeks following release (expressed as risk per 100 PY); 
(2) ACM and DRP mortality after 4 weeks to 1 year (expressed as risk per 100 PY); and 
admission to community drug misuse treatment in the first 4 weeks following release. DRP deaths 
were classified by the Office for National Statistics’ definition [26] using the following codes from 
ICD-10 and referencing the coroner’s inquest report and death certificate:   
 ‘Mental and behavioural disorders due to drug use’ (ICD-10 codes: F11-F16, F18, F19);  
 ‘Accidental poisoning by drugs, medicaments and biological substances’ (X40-X44);  
 ‘Intentional self-poisoning by drugs, medicaments and biological substances’ (X60-X64);  
 ‘Assault by drugs, medicaments and biological substances’ (X85); and  
 ‘Poisoning by drugs, medicaments and biological substances, undetermined intent’ (Y10-
Y14). 
Sample size calculation  
For the first 4 weeks, pooled risk estimates from two previous studies [8,27] suggested that there 
would be 3.4 deaths per 100 PY compared to 0.7 per 100 PY for adults with OUD in the 
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community. We estimated that a sample of 20,000 (50% OST exposed) would give at least 90% 
power to detect a five-fold or greater reduction in the mortality rate associated with prison-based 
OST exposure.  
Procedure 
We secured National Health Service research ethical approval for a recruitment procedure in which 
prison healthcare staff would identify and approach eligible prisoners and obtain their informed, 
signed consent1. Of the 43 prisons approached to participate in recruitment, four prisons (3 male 
and 1 female) were unable to take part because of the anticipated administrative burden or 
healthcare staff shortages.  
We provided on-site training on the study protocol for the remaining 39 prisons (32 for men and 7 
for women). As a check on representativeness, we noted that these institutions accounted for 95% 
of OST treatment in England during the study planning phase. As part of efforts to ensure that 
people would not feel obligated to take part, we stressed to the healthcare teams that prisoner 
participation was voluntary.  
Cohort recruitment started in September 2010. By April 2011 it was evident that we were not 
achieving the required level of recruitment. With the study steering committee’s agreement, we 
proposed to retain data to this point and then adopt a non-explicit consent procedure. This would 
involve display of posters at multiple points throughout each prison presenting study information 
and stating that eligible prisoners receiving OST would be included unless they requested to opt 
out. We provided in-prison training with healthcare staff on this procedure so that they would alert 
each prisoner who met the inclusion criteria to the poster and answer questions, and also discuss 
the study with those needing help with written English.  
This change was approved by the National Information Governance Board in August 20112, by the 
original ethics committee in November 2011, and by all local research governance offices in June 
2012. Recruitment recommenced under these arrangements in June 2012 and was completed in 
August 2013.  
                                                          
1 Essex NHS Research Ethics Committee (reference: 10/H0302/7; February 2010). 
2 Reference: ECC 5-04[d]/2011. 
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Data sources 
Information was collected from 5 centralised and local data sources, as follows:  
 Prison National Offender Management Information Service (P-NOMIS): prison where 
recruited; name, sex, date of birth (age grouped for analysis as follows: <30; 30 to 34; 35 to 
39; 40 years);  
 Prison IDTS healthcare provider: OST medication; dose at release; date of last dose if 
withdrawal regimen provided;  
 Justice Statistics Analytical Services (JSAS database): name of releasing prison and date;  
 Office for National Statistics, national deaths register, accessed from the Health and Social 
Care Information Centre (HSCIC): date of death and specified ICD-10 codes)3; 
 English National Drug Treatment Monitoring System (NDTMS): route of drug administration 
(injecting/other route); prisoner self-report of problem alcohol use; non-medical 
benzodiazepine use; cocaine use (all for past month before incarceration); date of 
admission to community drug misuse treatment (all types of structured interventions 
including OST) within 4 weeks following release4.  
Participant recruitment  
During the recruitment period (September 2010 to August 2013) each person was assigned a 
study identification number. As noted above, participants could be recruited multiple times (i.e. on 
each occasion of incarceration during the recruitment period). The risk set was identified in 3 
stages, as follows: 
Stage 1 
Prison healthcare services identified an initial sample of 22,623 prisoners. Of these, 567 were 
removed because they were administrative duplicates on P-NOMIS, and 56 people opted out and 
withdrew their consent.  
                                                          
3 There are extensive checks on accuracy for HSCIC but it is possible in all studies of this kind in England 
that in a small number of deaths, the person died abroad and there was a failure of registration. 
 
4 The search for community treatment in NDTMS used a probabilistic case matching protocol [28]. 
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Among the remaining 22,000 prisoners, 9,093 (41.3%) were convicted and sentenced, 7,956 
(36.2%) were on remand awaiting trial and 1,612 (7.3%) were in incarcerated for another reason 
(e.g. failure to meet conditions of probation). Sentence type information was not recorded for the 
remaining 3,339 prisoners (15.2%). In total, we recruited 3,769 participants (17.1%) by individual 
consent and 18,231 by the ‘opt-out’ procedure (82.9%). 
Stage 2 
From the JSAS database 1,368 of 22,000 people recruited were removed because they did not 
leave prison, and a further 2,186 were removed because a prison release date could not be 
verified. At completion of this stage, 18,446 prisoners were successfully matched to a release date.  
The number of prisoners recruited from the 39 recruiting prisons ranged from 41 to 1,704, and the 
number of prisoners released from prisons ranged from 40 to 1,366. An additional 84 prisons (79 
male and 5 female prisons) released 3,184 prisoners (17.2%) due to transfer across the system.  
Stage 3 
Of the 18,446 releases identified in Stage 2, HSCIC could flag 96% for monitoring on the deaths 
register (a loss of 770 people). After gathering all available OST information from IDTS healthcare 
records, we removed a further 2,527 releases because there was no medication information 
recorded, or because the healthcare provider was unable to undertake a manual search. 8 people 
were also removed because they had died in prison.  
At completion of this procedure, the risk set comprised 15,141 releases (relating to 12,260 people). 
The first release was in September 2010 and the last was in October 2014. We were notified of 
deaths by the HSISC until February 2016. 
Statistical analysis 
All analyses were done in Stata v14. The data contained one or more exposure and risk periods 
for each person. Risk periods were censored at the earliest date of re-entry into the study, or one 
year after release date. Kaplan Meier 1-year survival curves were plotted.  
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We fitted a Cox proportional hazards model, stratified by post-release period, to estimate hazard 
ratios ([HR], with associated 95% confidence intervals [CI]) for the ACM and DRP deaths during 
day 1 to 28, and months 2 to 4 (days 29 to 121), and months 5 to 12 (days 122 to 365). The 
assumption of proportional hazards within each of these periods was evaluated by plotting Nelson-
Aalen cumulative hazard estimates and testing for a linear relationship between scaled Schoenfeld 
residuals and logged time within each period [29]. Random effects (shared frailty) terms were 
included to adjust for potential clustering by prison of release. 
In addition to the unadjusted (crude) HRs, the following covariates (overdose risk factors) were 
included in a multivariable Cox regression for the 4-week mortality outcomes: sex; age group; drug 
injecting; problem alcohol use; non-medical benzodiazepine use; and cocaine use. We adjusted for 
the potential confounding factor of prison transfer (i.e. people released from a different prison to 
the one at entry), hypothesising that transfer could be associated with a reduced likelihood of OST 
exposure at release.  
Admission to community drug misuse treatment in the first 4 weeks was also incorporated as a 
time-varying covariate to test whether any effect of OST exposure at release could be accounted 
for by subsequent treatment. If no NDTMS record for community treatment could be found, the 
released prisoner was assumed not to have been admitted. The Likelihood Ratio Test (LRT) was 
used to test for evidence of mediation for community treatment and OST exposure on mortality 
risk. To assess further whether community treatment might be a mediator in any association 
between OST exposure and 4-week mortality, we fitted an additional Cox Proportional Hazards 
model with time to community treatment as the outcome variable (and OST at prison release as 
the exposure). For this analysis, risk periods were censored at the earliest point during the first 4-
weeks post-release, at re-entry into the study population, or death.  
So that all releases could contribute to the analysis, we multiply imputed missing covariate values 
using chained equations, assuming the missing values to be missing-at-random. Model estimates 
were based on 50 sets of imputed values and included the outcome measure, admission to 
community treatment, the estimated cumulative hazard for mortality and community treatment, and 
all other covariates [30,31].  
 11 
There were three sensitivity checks: Firstly, the analysis was repeated using only those releases 
with complete covariate information (a ‘complete case’ analysis). Second, we checked that the 
multiple prison releases of some people did not lead to spuriously precise results. Here, the 
'conditional gap time method' was used to stratify the baseline hazard by order of appearance in 
the study [31]. Finally, we compared the mortality risk from the time of entry to the study to 1-year, 
for releases that were linked to the deaths register but had missing information on prison release 
or OST exposure.  
RESULTS 
Among the 12,260 people in the risk set, 82.1% entered the study once. The remainder entered 
the study between 2 and 7 times by re-incarceration (n=2,194)5. The median time from recruitment 
to release was 60 days (inter-quartile range [IQR] 28 to 156 days). 
Intervention exposure and participant characteristics 
We classified 8,645 releases (57.1%) as OST exposed. Of these, 7,614 (88.1%) received 
methadone (median daily dose on the day of release was 40 mg [IQR 30 to 50 mg]) and 1,031 
(11.9%) received buprenorphine (median dose 8 mg [IQR 8 to 12 mg]). A minority of the OST 
exposure group was released from a different prison to the prison of recruitment (n=942; 10.9%). 
The remaining 6,496 releases (42.9%) were classified as OST unexposed. These included 2,369 
people (36.5%) prescribed lower daily dose medication; 2,110 (32.5%) who had been withdrawn 
from OST in prison; and 2,017 (31.0%) diagnosed with current OUD but with no record of OST.  
Table 1 shows the characteristics of the study participants in the intervention and comparator 
groups. The proportion of women was greater in the OST exposed group (24.1% versus 19.3%) 
due to proportionately more women’s prisons agreeing to participate in the study and relatively 
higher individual participation rates within these institutions. The OST exposed group had a higher 
proportion of people who injected drugs, used non-medical benzodiazepines and cocaine, and a 
lower proportion of problem drinkers.  
                                                          
5 Over half of the re-incarcerated offenders were sentenced, with the remainder remanded or in prison for 
another reason (e.g. breaking probation conditions).  
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Post-prison release mortality 
Within the first year of release, there were 160 deaths, of which 102 (63.8%) were DRP (mortality 
rate: 1.22 and 0.78 per 100 PY, respectively). The other 58 deaths were recorded as: suicide and 
other injury (n=22); liver disease due to viral hepatitis or alcohol (n=13); drug injection-related 
infection (n=5); respiratory disease (n=8); cardio-vascular disease (n=7); and other non-
communicable disease (n=3).  
Person follow-up time, mortality rates and number of deaths were as follows:   
 1 to 28 days (1,133 PY): ACM 2.12 per 100 PY (24 deaths); DRP 1.58 per 100 PY (18 
deaths);  
 29 to 121 days (3,521 PY); ACM 1.14 per 100 PY (40 deaths); DRP 0.68 per 100 PY (24 
deaths); and, 
 122 to 365 days (8,478 PY); ACM 1.13 per 100 PY (96 deaths); DRP 0.71 per 100 PY (60 
deaths). 
The survival curve for the OST exposed and unexposed groups for ACM and DRP mortality is 
displayed in Figures 1 and 2, respectively.  
Association between OST exposure and mortality 
Among the 24 ACM cases within 4 weeks of prison release, 6 were members of the OST exposed 
group and 18 were members of the OST unexposed group (mortality rate 0.93 per 100 PY versus 
3.67 per 100 PY; HR 0.25 [95% CI 0.10 to 0.64]).  
In the first 4 weeks, there were 18 DRP deaths. Three were members of the OST exposed group 
and 15 were members of the OST unexposed group (mortality rate 0.47 per 100 PY versus 3.06 
per 100 PY; HR 0.15; 95% CI 0.04 to 0.53).  
After the first 4 weeks, the mortality difference narrowed between the two groups (Figure S1). 
There was no evidence of between-group difference in risk of ACM or DRP mortality during the 
second to fourth month (29 to 121 days) and from the fifth month to 1 year (122 to 365 days; Table 
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2). There was no evidence against the proportional hazards assumption within any of these three 
periods (minimum P value 0.17) and no evidence of clustering of mortality by prison of release.  
 
Multivariable model of OST exposure on mortality  
Table 3 shows the unadjusted and adjusted analysis of OST exposure and mortality outcomes in 
the first 4 weeks. For ACM, the protective effect of OST exposure was not attenuated following 
adjustment for age and risk factors (adjusted HR 0.24; 95% CI 0.09 to 0.61), or by adjustment for 
community treatment (HR 0.28; 95% CI 0.11 to 0.71). The fully adjusted HR for all covariates, 
including prison transfer was 0.26 (95% CI 0.09 to 0.64). The protective effect of OST exposure on 
DRP mortality was similarly not attenuated (fully adjusted HR 0.15; 95% CI 0.04 to 0.52). There 
was also no evidence of mediation between community treatment and OST exposure on ACM 
(ratio of HR 0.97; 95% CI 0.12 to 7.97; LRT P value 0.98) or DRP mortality (ratio of HR 1.26; 95% 
CI 0.07 to 21.29; LRT P value 0.86).  
 
Community drug misuse treatment 
 
6,140 releases (40.6%) were admitted to drug misuse treatment within the first 4 weeks. The OST 
exposed group was more likely to enter treatment than the unexposed group (odds ratio 2.47, 95% 
CI 2.31-2.65). Following adjustment for clustering by prison (P value for clustering <0.001), the HR 
for being admitted to treatment was 2.13 (95% CI 2.01 to 2.25; with no evidence for non-
proportional hazards [P value 0.50]; Figure 3). There was no statistical association between 
community drug misuse treatment and the risk of ACM or DRP mortality (HR 0.51; 95% CI 0.19 to 
1.39 and HR 0.39; 95% CI 0.11 to 1.36, respectively), and no evidence of non-proportional 
hazards (P value 0.18 and 0.34, respectively). 
Sensitivity analyses 
With complete covariate information available on 86.9% of releases (missing observations for 
behavioural covariates: 10% to 16%), the ‘complete case’ analysis also showed a protective effect 
of OST exposure on mortality risk (Table S1).  
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In the check on multiple prison releases, we confirmed that multiple appearances of some study 
participants did not lead to spuriously precise estimates. With baseline hazard stratified by the 
participant’s release number, the HR for the association between OST exposure and 4 week ACM 
was 0.27 (95% CI 0.11 to 0.69).  
 
There were 2,082 releases linked to the deaths register with missing prison release information, 
and 2,526 with missing OST exposure information. Excluding those not released, the mortality rate 
for the former group was 0.93 per 100 PY compared to 0.92 per 100 PY among those with no 
missing prison release information (Incidence Rate Ratio [IRR] 1.01; 95% CI 0.43 to 2.05). For the 
latter group the mortality rate was 1.57 per 100 PY compared to 1.23 per 100 PY among those 
with no missing OST exposure information (IRR 1.27; 95% CI 0.86 to 1.84). 
 
DISCUSSION 
In this national study, OST exposure with oral methadone or buprenorphine removed the four-fold 
excess risk of death in the first 4 weeks after release for prisoners with OUD. OST was associated 
with a 75% reduction in ACM and an 85% reduction in DRP mortality. The protective effect of OST 
was not observed after the first month. Those in the OST exposed group were more than twice as 
likely to be admitted to community-based drug misuse treatment in the first month. 
Strengths of our study include: the large sample of prisoners with OUD; the use of administrative 
databases for recording OST exposure; outcome estimates subject to confounder control; and 
clinically important findings which apply to both the prison and community drug misuse treatment 
systems in England and elsewhere.  
We also acknowledge several study limitations: firstly, we were unable to report on the numbers of 
eligible prisoners who were approached and declined to take part the overall proportion of 
prisoners enrolled in OST across the 39 prisons. However, we believe it was unlikely that the 
revised procedure in our prospective design introduced a selection bias in relation to OST 
exposure and future mortality risk, and we received very few requests to opt out.  
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Second, some cases had to be removed because of duplication of records and matching failures, 
and some prisons were unable to give information on OST medication. Missing OST exposure and 
prison release data will have reduced statistical power, and we did not have sufficient samples to 
compare outcomes for men and women. However, we do not believe case attrition was likely to 
have introduced bias to the estimate of mortality risk. The protective effect of OST was not 
sensitive to imputation of missing confounders, and we showed that there were no differences in 
mortality risk for prisoners with or without missing data on prison release or OST exposure. 
Third, OST exposure was not randomised. However, we show that differences in OST exposure 
for people who inject drugs, those using other drugs, and for those transferred between prisons did 
not alter the strength or direction of our findings. Our analyses tested and examined the impact of 
behavioural confounders and community treatment and found a mutually beneficial association 
with no evidence of any interaction or mediation. Furthermore, we believe a selection bias was 
highly unlikely as the outcome had not occurred by the time exposure had been determined.  
Results in context  
The present findings align with a recent study of prison-based OST in New South Wales [33]. In 
this Australian study, the 4-week mortality rate after release comparing OST exposure and entry to 
community treatment versus no prison or community treatment was 0.64 and 3.67 per 100 PY, 
respectively. This is a slightly stronger protective effect than we observed, but this may be due to 
the exposure in the Australian study being continuous OST from prison to community in the first 
month, and for a greater potential for immortal time bias in this retrospective cohort design [34].  
A recent study conducted in Scotland reported an overall reduction in mortality risk after 
introduction of prison-based OST (from 3.8 to 2.2 per 1,000 releases) but observed no protective 
effect for OST in the immediate period following release [35]. The researchers were unable to 
identify the OUD population in the prisons studied, nor adjust for risk factors, but they concluded 
that: “in-prison OST does not reduce early deaths after release” (page 1,617). Our adjusted 
models provide strong evidence against this conclusion for England. 
Meaning of the study and its implications 
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Physiological tolerance to opioids is the most likely mechanism of protective effect for people who 
leave prison enrolled in OST with relapse vulnerability. If heroin is used there is a reduced 
likelihood of acute respiratory depression. OST will also prevent the onset of opioid withdrawal 
symptoms which may motivate illicit drug use.  
But how can the absence of protective effect after the first month following release be explained? 
We suspect that several factors are involved: some patients enrolled in community treatment will 
resume use of heroin, progressively returning to pre-prison levels; others will drop out of 
community treatment and relapse; and some people who are not enrolled in OST at release will 
present for community OST. Further studies are needed to explore these sub-populations and their 
trajectories and association with mortality outcome.  
Given an increasing global prison population, effective initiatives are needed to improve prisoners’ 
health and reduce the burden of infectious and chronic disease and other causes of premature 
mortality. Prison-based OST is scarce in the USA and there is little or no provision in many other 
countries. In this context, we frame our findings in the clinical management of OUD and prevention 
of overdose. Firstly, the importance of continuity of OST from the community to the prison system 
is supported unequivocally by our findings. OST in prison enables prisoners to engage with 
recovery services and there are also important public health benefits. For example, a low incidence 
of Hepatitis C virus has been reported in Scottish prisons with OST provision [36]. OST withdrawal 
regimens should not be overlooked, but we contend that withdrawing a patient in prison should be 
done with a careful appraisal of post-release support and with full discussion of the risks.  
Second, for prevention of fatal opioid overdose, a specific ex-post strategy is the supply of the 
short-acting opioid antagonist naloxone to prisoners at release for acute administration in the 
community. This strategy has not been implemented in English prisons to date. Encouragingly, the 
first two years of the national naloxone programme in Scotland were associated with a 36% 
reduction in the proportion of opioid-related deaths that occurred in the first month after release 
[37].  
Third, for those with OUD who are abstinent from all opioids and have been appropriately informed 
and consented, there is also an opportunity to use the long-acting opioid antagonist, naltrexone, as 
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an ex-ante relapse prevention therapy. A 50 mg tablet of naltrexone blocks the effects of opioids 
for approximately 24 hours; an extended-release, intramuscular injection is also available. This 
treatment has not been systematically implemented in English prisons and is not viable for 
everyone (e.g. contraindication in liver disease and for some with chronic non-malignant pain). 
However, the feasibility of extended-release naltrexone has recently been demonstrated in two 
open-label trials in the USA (one study using an injection before prison release; the other using 
monthly injections in the community) [38,39].  
Conclusion 
Opioid overdose is a major public health problem in many countries. People with OUD who reduce 
or stop using non-medical opioids while incarcerated face an acute risk of death on release if they 
use these drugs again. Our study shows that prison-based OST (with oral methadone or oral 
buprenorphine) is a highly effective means of reducing the risk of death among prisoners in the first 
4 weeks after release. The clinical decision to withdraw prisoners from OST should be made with 
care and with further support.  
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Table 1: Demographic and characteristics of people in the risk set  
by intervention exposure status at prison release (n=12,260) 
 
 
 
OST 
Exposed  
(n = 6,662) 
OST 
Unexposed  
(n = 5,598) 
Odds ratio  
or mean difference 
(95% CI) 
 
Men, n (%)  5,054 (75.9) 4,515 (80.7) 0.75 (0.69 to 0.82) 
Age, years (SD)  34.6 (7.1) 34.6 (8.0) 0.00 (-0.30 to 0.20) 
Drug injecting, n (%) a 
Missing data, n (%) 
4,167 (72.1) 
   885 (13.3) 
2,648 (56.3) 
   895 (16.0) 
2.01 (1.85 to 2.18) 
Problem alcohol use n (%)  
Missing data, n (%) 
1,724 (28.7) 
   660 (9.9) 
1,763 (35.8) 
   675 (12.1) 
0.72 (0.67 to 0.78) 
Non-medical benzodiazepine use, n (%)  
Missing data, n (%) 
1,504 (25.0) 
   638 (9.6) 
   870 (17.6) 
   658 (11.8)   
1.56 (1.42 to 1.71) 
Cocaine use, n (%)  
Missing data, n (%) 
2,438 (40.5) 
   638 (9.6) 
1,741 (35.2) 
   658 (11.8) 
1.25 (1.16 to 1.35) 
 
OST, opioid substitution treatment; CI, confidence interval. 
a Injecting versus other route of drug administration (score: 1,0). 
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Figure 1: Survival curve during the year following release  
(all-cause mortality) 
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Figure 2: Survival curve during the year following release  
(drug-related poisoning mortality) 
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Table 2: Person years, mortality rates and hazard ratios for ACM and DRP mortality,  
by intervention exposure at prison release and follow-up period  
 
ACM   
 OST exposed  OST unexposed  
Period PY at risk  
(n deaths) 
Rate per 100 PY  
(95% CI) 
PY at risk  
(n deaths) 
Rate per 100 PY 
(95% CI) 
HR (95% CI)§ 
  1 to 28 days    643 (6) 0.93 (0.42 to 2.08)    490 (18) 3.67 (2.31 to 5.83) 0.25 (0.10 to 0.64) 
  29 to 121 days 1,966 (23) 1.17 (0.78 to 1.76) 1,555 (17) 1.09 (0.68 to 1.76) 1.07 (0.57 to 2.00) 
  122 to 365 days 4,654 (52) 1.12 (0.85 to 1.47) 3,824 (44) 1.15 (0.86 to 1.55) 0.97 (0.65 to 1.45) 
 
DRP mortality 
   
 OST exposed OST unexposed  
Period PY at risk  
(n deaths) 
Rate per 100 PY  
(95% CI) 
PY at risk  
(n deaths) 
Rate per 100 PY 
(95% CI) 
HR (95% CI) § 
  1 to 28 days    643 (3) 0.47 (0.15 to 1.45)    490 (15) 3.06 (1.85 to 5.08) 0.15 (0.04 to 0.53) 
  29 to 121 days 1,966 (13) 0.66 (0.38 to 1.14) 1,555 (11) 0.71 (0.39 to 1.28) 0.93 (0.42 to 2.08) 
  122 to 365 days 4,654 (31) 0.66 (0.47 to 0.94) 3,824 (29) 0.76 (0.53 to 1.09) 0.88 (0.53 to 1.46) 
 
ACM, all-cause mortality; DRP, drug-related poisoning mortality;  
OST, opioid substitution treatment; 
PY, person years; CI, confidence interval; HR, unadjusted HR ratio.  
§  There was no statistical evidence of non-proportional hazards within each period (P > 0.05).  
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Table 3: Covariate adjusted effect of OST exposure at prison release 
on ACM and DRP mortality in the first 4 weeks (n = 15,141) 
  ACM  
(primary outcome)  
DRP 
mortality 
Model  HR (95% CI) HR (95% CI) 
OST (unadjusted) a  0.25 (0.10 to 0.60) 0.15 (0.04 to 0.53) 
OST + age group b  0.26 (0.10 to 0.65) 0.15 (0.04 to 0.53) 
OST + injecting c  0.23 (0.09 to 0.59) § 0.14 (0.04 to 0.47) § 
OST + problem alcohol use   0.26 (0.10 to 0.65) § 0.16 (0.05 to 0.54) § 
OST + non-medical benzodiazepine use  0.25 (0.10 to 0.62) § 0.14 (0.04 to 0.50) § 
OST + cocaine use   0.26 (0.10 to 0.66) § 0.16 (0.05 to 0.54) § 
OST + demographic and clinical covariates  0.24 (0.09 to 0.61) § 0.14 (0.04 to 0.47) § 
OST + prison transfer d 0.25 (0.10 to 0.63) 0.15 (0.04 to 0.51) 
OST + community treatment e  0.28 (0.11 to 0.71)  0.17 (0.05 to 0.59)  
OST + all covariates f  0.25 (0.09 to 0.64) § 0.15 (0.04 to 0.52) § 
 
ACM, all-cause mortality; DRP, drug-related poisoning mortality; 
OST, opioid substitution treatment; HR, hazard ratio; CI, confidence interval.  
§ Multiply imputed analysis with all releases. These analyses did not include shared frailty 
terms (random effects) for prison of release;  
a OST exposed versus OST unexposed (scored: 1,0); 
b Age group: <30, 30 to 34, 35 to 39,  40 years (no missing observations); 
c Injecting (current/lifetime versus never; scored: 1,0);  
d Prison of release different from recruitment prison 
e Admitted to community drug misuse treatment within 4 weeks (time varying covariate). 
f i.e. all demographic, clinical, prison transfer and community treatment measures 
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Figure 3: Time to admission to community drug misuse treatment in first 4 weeks after 
prison discharge by OST prison exposure: Kaplan-Meier plot. 
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SUPPLEMENTARY MATERIAL 
 
Figure S1: Plot of Nelson-Aalen estimates of cumulative hazard – comparing those OST 
exposed and unexposed to 1 year months after prison release 
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Table S1: Covariate adjusted effect of OST exposure at prison release  
on ACM and DRP mortality in the first 4 weeks: complete case analysis (n = 13,158) 
  ACM 
(primary outcome)  
DRP 
mortality 
Model  HR (95% CI) HR (95% CI) 
OST (unadjusted) a ¶ 0.31 (0.11 to 0.88) 0.20 (0.06 to 0.72) 
OST + age group b ¶ 0.30 (0.11 to 0.86) 0.20 (0.06 to 0.71)  
OST + injecting c  0.28 (0.10 to 0.80) 0.18 (0.05 to 0.65) 
OST + problem alcohol use   0.31 (0.11 to 0.90) 0.21 (0.06 to 0.74) 
OST + non-medical benzodiazepine use  0.30 (0.10 to 0.85) 0.19 (0.05 to 0.68) 
OST + cocaine use   0.32 (0.11 to 0.91) 0.21 (0.06 to 0.75) 
OST + demographic and clinical covariates  0.28 (0.10 to 0.82) 0.18 (0.05 to 0.66) 
OST + prison transfer d 0.29 (0.10 to 0.82) 0.18 (0.05 to 0.65) 
OST + community treatment e ¶ 0.33 (0.11 to 0.96) 0.22 (0.06 to 0.80) 
OST + all covariates f 0.29 (0.10 to 0.84) 0.18 (0.05 to 0.66) 
 
ACM, all-cause mortality; DRP, drug-related poisoning mortality; 
OST, opioid substitution treatment; HR, hazard ratio; CI, confidence interval.  
a OST exposed versus OST unexposed (scored: 1,0); 
b Age group: <30, 30 to 34, 35 to 39,  40 years  
c Injecting (current/lifetime versus never; scored: 1,0);  
d Prison of release different from recruitment prison 
e Admitted to community drug misuse treatment within 4 weeks (time varying covariate);  
f i.e. all demographic, clinical, prison transfer and community treatment measures 
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